Congress quietly extends drug-price exemptions for pharmaceutical companies
H.R. 946 — ORPHAN Cures Act · Filed by John Joyce (R-PA) · 18 cosponsors · Introduced Feb 4, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill expands the orphan drug exemption from Medicare's drug price negotiation program. It allows drugs that were once designated as orphan drugs (for rare diseases affecting fewer than 200,000 people) to retain their exemption even after they are approved for broader uses, and clarifies that the time a drug spent under orphan status does not count toward the eligibility clock for price negotiation. This benefits pharmaceutical companies by extending the period during which they can charge higher prices without Medicare negotiation.
Why we flagged it
The bill's operative mechanism is to extend the orphan-drug exemption from Medicare price negotiation to drugs that were formerly orphan-designated but now treat multiple rare diseases. This is a direct carve-out that protects pharmaceutical pricing power and delays price negotiation.
What the text implies
- Drugs approved for multiple rare diseases (e.g., a cancer drug approved for three different rare cancers) can now claim orphan status for each indication separately, potentially extending exemption indefinitely as new rare-disease approvals accumulate.
- The bill does not require disclosure of how many patients actually use a drug for each rare-disease indication, creating potential for gaming: a drug with minimal rare-disease use but large non-rare-disease population could retain exemption based on small patient populations.
The full analysis lists 4 implications of this text.
Who stands to gain
pharmaceutical companies with orphan-designated drugs; specialty pharmaceutical manufacturers; biotech firms developing rare-disease treatments